Search clinical trials for: MRx0029

Total 15 results

4D pharma plc
ICON plc; Labcorp Drug Development Inc

Withdrawn

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Idiopathic Parkinson Disease
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Locally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Breast Cancer With Liver Metastases

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China

3

Subscribe